Ilmn stock price forecast investment banks updating ilmn stock

Investment banks updating ilmn stock price forecast advise cautious optimism. The biotech capital markets show resilience, and Illumina’s healthy balance sheet with over $1.5B in cash reserves provides flexibility for R&D scaling in 2024– The company’s fiscal Q4 2024 results reflect growth potential and resilience, with core revenue reaching $1.1 billion and reflecting a 1% growth from fiscal Q4 2023. Illumina, Inc. (NASDAQ:ILMN) also improved its operating margins, with GAAP operating margin at 15.8% and non-GAAP at 19.7%. In a report released on March 12, Mason Carrico from Stephens maintained a Buy rating on the company with a price target of $156.00. We just received data on a new analyst forecast for $ILMN. Sung Ji Nam from Scotiabank set a price target of 125.0 for ILMN. The ilmn stock price forecast also factors in Illumina’s strategic focus on core sequencing technology. Analysts see reduced distractions from non-core investments as a positive for operational agility.